Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edgewise Therapeutics (EWTX) Non-Current Assets (2020 - 2026)

Edgewise Therapeutics has reported Non-Current Assets over the past 7 years, most recently at $8.7 million for Q1 2026.

  • Quarterly results put Non-Current Assets at $8.7 million for Q1 2026, down 22.14% from a year ago — trailing twelve months through Mar 2026 was $37.6 million (down 19.33% YoY), and the annual figure for FY2025 was $9.2 million, down 18.67%.
  • Non-Current Assets reached $8.7 million in Q1 2026 per EWTX's latest filing, down from $9.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $13.6 million in Q2 2023 and bottomed at $4.1 million in Q2 2022.
  • Median Non-Current Assets over the past 5 years was $11.2 million (2025), compared with a mean of $10.3 million.
  • The largest annual shift saw Non-Current Assets surged 674.05% in 2022 before it fell 22.14% in 2026.
  • Over 5 years, Non-Current Assets stood at $10.1 million in 2022, then grew by 29.06% to $13.0 million in 2023, then decreased by 13.07% to $11.3 million in 2024, then dropped by 18.67% to $9.2 million in 2025, then fell by 5.29% to $8.7 million in 2026.
  • Business Quant data shows Non-Current Assets for EWTX at $8.7 million in Q1 2026, $9.2 million in Q4 2025, and $9.6 million in Q3 2025.